Implantable neurostimulators market seen topping $11.4 billion by 2030

The implantable neurostimulators market is forecast to grow from $6.76 billion in 2025 to $11.44 billion by 2030 as neurological disorders rise and device technology advances. North America led the market in 2025, while Asia-Pacific is expected to grow fastest.

Why it matters: - Implantable neurostimulators are becoming a larger part of treatment for chronic pain and neurological disorders. - The market is expanding quickly as more patients and providers turn to device-based therapies instead of drug-only pain relief. - Faster growth in this category points to rising demand for neuromodulation, especially among aging populations.

What happened: - The Business Research Company projected the global implantable neurostimulators market will rise from $6.76 billion in 2025 to $7.52 billion in 2026. - The report forecasts the market will reach $11.44 billion by 2030. - The report puts 2025-2026 growth at 11.4% and 2026-2030 growth at 11.0%. - North America held the largest market share in 2025. - Asia-Pacific is expected to be the fastest-growing region during the forecast period. - The report also covers South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa.

The details: - Implantable neurostimulators deliver targeted electrical impulses to the nervous system to modify nerve activity or regulate nerve function. - The devices are used mainly for chronic pain and neurological disorders. - The market’s recent growth has been driven by more chronic pain cases, early adoption of spinal cord stimulation, fewer effective drug-based pain alternatives, more neurological diagnoses and more hospital-based neurosurgical procedures. - Future growth is expected to come from advances in neurostimulation technology, wider use in Parkinson’s disease and epilepsy, a growing elderly population, stronger clinical evidence and better reimbursement and access. - Expected market trends include greater use in chronic pain management, higher demand for rechargeable devices, more minimally invasive neuromodulation treatments, broader therapeutic uses beyond pain and movement disorders, and longer device life with better patient comfort. - The World Federation of Neurology reported in October 2023 that more than 40% of the world’s population experiences some form of neurological disorder, and that figure is expected to nearly double by 2050. - The report includes new analytical features such as market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technology analysis and updated graphics and tables. - The report offers a free sample and the full market report through the sample request page and the full report page.

Between the lines: - The forecast suggests neuromodulation is moving from a niche option into a broader mainstream treatment category. - North America’s lead likely reflects deeper clinical adoption and stronger healthcare infrastructure, while Asia-Pacific’s growth outlook points to room for new procedures and device penetration. - The emphasis on rechargeable, minimally invasive and longer-lasting devices shows the market is competing on convenience as much as clinical performance.

What's next: - The market will likely keep scaling as evidence for neuromodulation expands and reimbursement improves. - Broader use in Parkinson’s disease, epilepsy and other indications could widen the customer base beyond chronic pain. - Device makers will likely focus on durability, comfort and lower procedural burden to differentiate products.